PHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 84-90

  Brunner, A ^a   Riss, P ^a   Heinze, G ^b   Brustmann, H ^a  

^a Landesklinikum Thermenregion Moedling Vienna ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Endometrial carcinoma; immunohistochemistry; pHH3; prognosis; survivin

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOHISTONE H3; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HISTONES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84862978461     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.198     Document Type: Article

References (34)

1. Altieri DC (2010) Survivin and IAP proteins in cell death mechanisms. Biochem J 430: 199-205
2. Beardmore VA, Ahonen LJ, Gorbsky GJ, Kallilo MJ (2004) Survivin dynamics increase at centomeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 117: 4033-4042 (Pubitemid 39328292)
3. Brenner RM, Slayden OD, Rodgers WH, Critchley OD, Caroll R, Nie XJ, Mah K (2003) Immunocytochemichal assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 18: 1185-1193 (Pubitemid 36740562)
4. Brustmann H, Hinterholzer S, Brunner A (2011) Immunohistochemical expression of survivin and g-H2AX in vulvar intraepithelial neoplasia and low-stage squamous cell carcinoma. Int J Gynecol Pathol 30: 583-590
5. Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardie TW, Glass LF (2010) Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 32: 650-654
6. Christian H, Nyholm J, Nielsen AL, Norup P (1993) Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: Comparison of clinical and histopathological characteristics. Gynecol Oncol 49: 229-235 (Pubitemid 23169996)
7. Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc Series B 34: 187-220
8. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynaecological cancer. Int J Gynecol Obstet 95: 105-143
9. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, Demirhan B (2006) Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 16: 1412-1418 (Pubitemid 43886778)
10. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E (2007) COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 104: 320-325 (Pubitemid 46135664)
11. Gemer O, Uriev L, Voldarsky M, Gdalevich M, Ben-Dor D, Barak F, Anteby EY, Lavie O (2009) The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. Eur J Surg Oncol 35: 247-251
12. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141-1154
13. Habberstad AH, Gulati S, Torp SH (2011) Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas-an immunohistochemical study. Diagn pathol 6: 43
14. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387 (Pubitemid 26072233)
15. Heinze G, Schemper M (2001) A solution to the problem of monotone likelihood in cox regression. Biometrics 57: 114-119 (Pubitemid 32200144)
16. Hendzel MJ, Wei Y, Mancini MA, van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD (1997) Mitosis specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106: 348-360 (Pubitemid 27510848)
17. Ioffe OB, Papadimitriou JC, Drachenberg CB (1998) Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proloferative, hyperplastic, and malignant endometrium. Hum Pathol 10: 1150-1159 (Pubitemid 28467539)
18. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
19. Kim YJ, Ketter R, Steudel WI, Feiden W (2007) Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 128: 118-125 (Pubitemid 47121724)
20. Lambropoulou M, Papadopoulos N, Tripsianis G, Alexiadis G, Pagonopoulou O, Kiziridou A, Liberis V, Kakolyris S, Chatzaki E (2010) Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol 136: 427-435
21. Li F, Yang J, Ramnath N, Javle MM, Tan D (2005) Nuclear or cytoplasmic expression of survivin: What is the significance? Int J Cancer 114: 509-512 (Pubitemid 40349608)
22. Markova I, Duskova M, Lubusky M, Kudela M, Zapletalova J, Prochazka M, Pilka R (2010) Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer 20: 576-582
23. Morsi HM, Leers MP, Jager W, Björklund V, Radespiel-Tröger M, el Kabarity H, Nap M, Lang N (2000) The patterns of expression of an apoptosis related CK 18 neoepitope, the bcl-2 proto.oncogene, and the Ki67 proliferation marker innormal, hyperplastic, and malignant endometrium. Int J Gynecol Pathol 19: 118-126 (Pubitemid 30212147)
24. Mutch D (2009) FIGO Committee on Gynecologic Oncology. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 115: 325-328
25. Nasr MR, El-Zammar O (2008) Comparison to pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 30: 117-122 (Pubitemid 351441982)
26. Nucci MR, Oliva E (2009) Endometrial Neoplasia. In: Matias-Guiu X (ed). Gynecologic Pathology. Elsevier Churchill Livingstone: Philadelphia, PA, USA, pp 233-259
27. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias Guiu X (2005) Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 24: 247-253 (Pubitemid 40885078)
28. Pirog EC, Czerwinski W (1992) Diagnostic and prognostic significance of the mitotic index in endometrial adenocarcinoma. Gynecol Onco 46: 337-340
29. Shah SS, Mazur MT (2008) Endometrial eosinophillic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol 27: 534-538
30. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak P (2007) Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 20: 1307-1315 (Pubitemid 350126856)
31. Steinbakk A, Skaland I, Gudlaugsson E, Janssen EA, Kjellevold KH, Klos J, Lovslett K, Fiane B, Baak JP (2009) The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. Am J Obstet Gynecol 78: e1-e8
32. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) Survivin expression correlates with clinical stage, histological grade, invasive behaviour and survival rate in endometrial carcinoma. Cancer Lett 184: 105-116 (Pubitemid 34718112)
33. Tornos C, Silva EG, el-Naggar A, Burke TW (1992) Aggressive stage I grade 1 endometrial carcinoma. Cancer 70: 790-798
34. Veras E, Malpica A, Deavers MT, Silva EG (2009) Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 28: 316-321